clinical trial · NCT06880549
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.·phase1·recruiting·n = 42
Advanced Solid TumorsmRNA-4106PembrolizumabmRNA-4200
brief summary
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
started
Mar 25, 2025
primary completion
Aug 3, 2027
completion
Aug 3, 2027
last updated
Aug 10, 2026
official title
A Phase 1, Open-label, Multicenter, Dose-escalation Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol